Table 3. Factors predicting Public Disclosure of Results (PDOR) of completed studies (publication and/or posting to ClinicalTrials.gov (CTG) website).
| Median Days to Transparency (95% CI) | Log-Rank test p value | Adjusted Hazard Ratio (95% CI) | |
| Funding (n) | |||
| Non-Industry or Blended (143) | 843 (694–1039) | 0.21 | 1 |
| Industry only (241) | 968 (785–1126) | 0.84 (0.63–1.12) | |
| Study Phase (n) | |||
| Phase 3 or 4 (186) | 706 (602–789) | <0.001 | 1 |
| Phase 2 (198) | 1176 (1002–1308) | 0.60 (0.47–0.78) | |
| Gender (n) | |||
| Male or female only (39) | 1121 (844 -) | 0.16 | |
| Both male and female (345) | 883 (744–1002) | ||
| Age Group (n) | |||
| Child involved (64) | 667.5 (526–833) | <0.001 | 1 |
| Adult only (320) | 992 (870–1174) | 0.61 (0.45–0.83) | |
| Randomization (n) | |||
| Not randomized (119) | 787 (684–947) | 0.069 | 1 |
| Randomized (264) | 982 (844–1134) | 0.62 (0.46–0.83) | |
| Investigator (n) | |||
| Academia (151) | 947 (730–1186) | 0.89 | |
| Non-academia (233) | 888 (751–1072) | ||
| Number of Study Subjects (n) | |||
| >50 (254) | 827.5 (731–969) | 0.008 | 1 |
| ≤50 (121) | 1178 (919–1504) | 0.60 (0.44–0.83) | |